New business, medical and technology heads at Neutrolis

Neutrolis Inc. named Michael Fleming chief business and strategy officer, Andreas Reiff CMO, and Ralph Lambalot CTO. Fleming was president of a life sciences advisory firm, before which he was chief strategy officer of Coherus Biosciences Inc. (NASDAQ:CHRS). Reiff was SVP of immunology and inflammation at Parexel International Corp., and Lambalot was VP of operations science and technology at Abbvie Inc. (NYSE:ABBV). Neutrolis is developing therapies targeting neutrophil extracellular traps.

CNS disorders play Noema Pharma AG hired Volker Knappertz as EVP of R&D. Knappertz was EVP of R&D at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)...